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Summary 
Early noninfectious pulmonary complications represent a significant cause of mortality after 
hematopoietic cell transplantation (HCT).  We tested the hypothesis that oral beclomethasone 
dipropionate (BDP) is effective for preventing early noninfectious pulmonary complications after 
allogeneic HCT.  We retrospectively reviewed medical records of 120 patients, 60 in each 
treatment arm. to identify noninfectious and infectious pulmonary events and prospectively 
collected pulmonary function test results from all patients who participated in two randomized 
trials of oral BDP for treatment of acute gastrointestinal graft-versus-host disease.  17-
beclomethasone monopropionate (17-BMP), the active metabolite of BDP, was evaluated in 
blood from the right atrium.  Among placebo treated patients, 33 of 42 (79%) patients 
experienced a decrease of the DLCO from pretransplant to day 80 after transplant, compared to 
27 of 49 (55%) BDP-treated patients (p=0.02).  In the first 200 days after randomization, there 
were no cases of noninfectious pulmonary complications in BDP-treated patients, versus four 
cases among placebo-treated patients (p=0.04). Levels of 17-BMP were detected in atrial blood 
at steady state.  Delivery of a potent glucocorticoid such as 17-BMP to the pulmonary artery 
after oral dosing of BDP may be useful in modulating pulmonary inflammation and preventing 
the development of noninfectious pulmonary complications after allogeneic HCT.   
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Pulmonary complications after allogeneic hematopoietic cell transplantation (HCT) remain a 
major cause of morbidity and mortality.  Among the estimated 50,000 to 60,000 hematopoietic 
cell transplants performed each year (www.ibmtr.org), approximately 30% to 60% of the 
transplant recipients will experience a pulmonary complication.1,2  While significant progress has 
been made in the prevention, diagnosis, and treatment of opportunistic pulmonary infections, 
particularly infections caused by viral and fungal infections, no advances have been made in the 
prevention, diagnosis, and treatment of HCT-related early noninfectious pulmonary syndromes 
such as idiopathic pneumonia syndrome (IPS) and diffuse alveolar hemorrhage (DAH).  These 
syndromes represent diffuse interstitial noninfectious pulmonary processes that are suspected 
to be caused by a spectrum of insults, including the toxic effects of conditioning regimens, 
immunologic cell-mediated injury, inflammatory cytokines, or occult pulmonary infections.3-14  
When these syndromes occur, they are associated with a high mortality rate of 60-100%, 
despite aggressive support in a critical care setting and treatment with high-dose systemic 
corticosteroids. 
Two multi-center randomized placebo-controlled, double-blind trials have been 
conducted to examine whether oral beclomethasone dipropionate (BDP) is an effective therapy 
for treatment of gastrointestinal graft-versus-host disease (GVHD).15,16  The results of these 
studies indicate that oral BDP is effective for treating gastrointestinal GVHD, allows rapid taper 
and less use of systemic corticosteroid therapy, and results in a 45% reduction in mortality risk 
at one year post-randomization.  In addition to these benefits, the most recent multi-center trial 
revealed that BDP treatment was also associated with fewer cytomegalovirus reactivations 
(28% versus 39%), fungal infections, (7% versus 14%), and multiple bacteremic episodes (none 
versus 9%).16  Of interest to the pulmonary community was an observation in the phase II study, 
12/67 (18%) patients on the placebo arm had developed noninfectious pulmonary infiltrative 
disorders, compared to 0/62 patients in the BDP treatment arm.17  Based upon this initial 
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observation, we developed the hypothesis that oral BDP may be effective in preserving lung 
function and preventing the development of early noninfectious pulmonary complications after 
allogeneic HCT.  However, recognizing the potential for misclassification among different 
centers, we decided to test this hypothesis by evaluating all patients who participated in both 
randomized trials conducted at our Center.  The current analysis was restricted to patients 
treated at our Center because all patients at our Center were evaluated using standardized 
prospective pulmonary evaluations and a clinical evaluation algorithm in place during both 
randomized trials.  In addition, our Center has near complete follow-up of all clinical events after 
discharge from our Center through the Long Term Follow-up Clinic.15 
Methods 
Patient selection 
All Fred Hutchinson Cancer Research Center (FHCRC, also referred to as Center) patients 
enrolled in two randomized placebo-controlled trials of oral BDP for the treatment of acute 
gastrointestinal GVHD were included in the current analysis.15,16  The first study was a single-
center, Phase 2 trial conducted between 1994 and 1996 that enrolled 60 patients; 29 received 
oral BDP 8 mg/day, 31 received placebo.15  The second study was a multi-center Phase 3 trial 
conducted between 2001 and 2005 that enrolled a total of 129 patients, including 60 patients at 
the FHCRC, of whom 31 patients received oral BDP and 29 patients received placebo.16  
Patients enrolled at other institutions were not included in this analysis because of the lack of 
pulmonary function monitoring and potential differences in clinical definitions of pulmonary 
syndromes (see below).  Both protocols and the current retrospective review were approved by 
our Institutional Review Organization. 
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Description of Randomized, Placebo-Controlled, Double-Blind Trials of Oral BDP 
Details of the two randomized trials have been previously described.15,16  Briefly, patients with 
biopsy-proven acute gastrointestinal GVHD received an induction course of prednisone (1 
mg/kg/day for 10 days) plus either oral BDP pills (8 mg/d in four divided doses, half as a gastric-
release formulation and half as an enteric-coated formulation) or placebo.  Patients whose 
symptoms were controlled at study day ten continued on study drug while the prednisone dose 
was rapidly tapered.  Patients whose symptoms required additional prednisone were considered 
treatment failures; study drug was discontinued on the day of treatment failure.  The duration of 
treatment with study drug was 30 days with a 10-day follow-up period in the first trial15 and 50 
days with a 30-day follow-up period in the second trial.16  Based upon recommendations from 
the U.S. Food & Drug Administration, all patients in the Phase III study were followed for clinical 
events until day 200 after randomization.  At our Center, detailed information about patient 
outcomes during the first year after transplant is gathered by our Long-Term Follow-Up office.  
Although the day 200 post-randomization endpoint had not been pre-specified in the protocol for 
the Phase II study of oral BDP vs. placebo, all patients in the Phase II study were also followed 
through our Long Term Follow-Up office using identical clinical protocols.   
Pulmonary function testing 
All PFTs were performed at our Center according to American Thoracic Society guidelines.18-20  
Pulmonary function assessments included forced vital capacity (FVC), one-second forced 
expiratory volume (FEV1), total lung capacity (TLC), and carbon monoxide diffusion capacity 
(DLCO), which was adjusted for hemoglobin level at the time PFTs were obtained.  All PFT 
values were expressed as a percent of the predicted value calculated according to published 
equations.21,22  As part of our standard practice, pretransplantation and day-80 PFTs were 
obtained regardless of the presence or absence of symptoms. For purposes of the current 
study, we considered PFTs performed between days 60 and 100 as valid for the day-80 PFT.  
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Change in lung function was assessed by comparing PFT parameters performed prior to start of 
conditioning to those obtained post-transplantation at day 80.  Analysis of change in lung 
function was done on an intent-to-treat basis, by randomization assignment to oral BDP or 
placebo, with maintenance of the study blind. 
Clinical follow-up and categorization of pulmonary disease after hematopoietic cell 
transplantation 
All patients in both trials were monitored according to the Standard Practice Manual of the FHCRC.  
While at our Center, this included daily evaluation for pulmonary symptoms, the presence of which 
would prompt physiologic and radiographic evaluation, followed by pulmonary and infectious diseases 
subspecialty consultation when deemed appropriate.  Microbiologic studies are pursued according to 
recommendations from these services.  Upon discharge from our Center, the patients are followed by 
the Long Term Follow-Up office, which remains in close contact with the patient and their healthcare 
provider for the first year after transplant.  Should pulmonary issues arise, recommendations are made 
according to our Standard Practice Manual.  All recommendations and clinical events are documented 
in our electronic records, which were reviewed for case designation.  
While blinded to randomization assignment, two investigators (JWC and MS) reviewed 
all patients’ pulmonary radiologic records accumulated from the time of randomization. The 
medical records of all patients with abnormal pulmonary radiological findings were reviewed to 
determine whether the pulmonary disease was a clinically significant noninfectious or infectious 
syndrome.  Clinically significant noninfectious pulmonary syndromes included idiopathic 
pneumonia syndrome (IPS), defined as widespread alveolar injury in the absence of active 
lower respiratory tract infection after HCT23; diffuse alveolar hemorrhage (DAH), defined as IPS 
with bronchioalveolar lavage showing progressively bloodier return5; or biopsy-proven 
cryptogenic organizing pneumonia (COP) otherwise known as bronchiolitis obliterans organizing 
pneumonia.(BOOP) 24,25  All clinically significant pulmonary infections required microbiologic 
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documentation of an infectious agent in the respiratory tract via bronchoscopy or resolution of 
pulmonary abnormalities after empirical antibiotic therapy with no addition of 
immunosuppressive agents.    
Measurement of 17-beclomethasone monopropionate (17-BMP) in blood from the right atrium 
Four FHCRC patients enrolled in the Phase 3 randomized study had participated in an analysis 
of BDP pharmacokinetics.  At study day 50, blood was drawn from the right atrium via an 
indwelling Hickman catheter at frequent intervals after a morning dose of oral BDP 2 mg (1 mg 
each in gastric-release and enteric-coated tablets).  Blood samples were collected over EDTA, 
plasma was collected after centrifugation at 4°C, and aliquots were frozen at -20°C until analysis 
for BDP and 17-BMP using high-pressure liquid chromatography and mass spectroscopy (MDS 
Pharma Services, Montreal, Canada).  Pharmacokinetic parameters were calculated using 
WinNonlin v.2.1 (Pharsight Corp, Palo Alto CA).  Plasma concentration-time data were plotted 
and non-compartmental parameters were calculated using the linear trapezoidal rule.  Estimates 
for half-lives were obtained using regression analysis by specifying an appropriate range of time 
points for the most linear portions of the log concentration-linear time data.  
Statistical analysis  
All statistical analyses were performed using SAS (version 8.2; SAS Institute, Cary, NC), R 
(freeware; version 2.0.1), and S-Plus (version 6.2; Insightful, Seattle, WA) software.  P-values ≤ 
0.05 were considered statistically significant.  Change in pulmonary function test parameters 
was analyzed by comparing the proportion of patients in the treatment groups who experienced 
a decrease of each PFT parameter from pretransplantation to day 80 using the chi-square test.  
Average change from baseline to day 80 was compared using the two-sample t-test.  
Cumulative incidence curves were used to summarize the probability of the time-to-event 
endpoints noninfectious and infectious pulmonary events, where death without the respective 
pulmonary event was considered a competing risk.  For these endpoints, the hazard ratio (HR) 
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for failure was estimated based on a Cox proportional hazards model that included a term for 
treatment group.  No additional covariates were included in the model for noninfectious 
complications due to the low number of events in the study.  Patients alive without failure for the 
pulmonary time-to-event endpoints at day 200 after randomization were censored at these times 
as appropriate.  
Results 
There were 120 randomized patients from our Center available for this analysis, 60 received 
oral BDP and 60 received placebo.  The characteristics of these patients are summarized in 
Table 1.  In the analysis of change in PFTs from baseline to day 80, eight patients who did not 
meet the minimum five-day criterion of treatment with study drug prior to their day-80 PFT were 
not included (five in placebo group, three in BDP group).  The median time to randomization 
was 33.5 days after HCT (range, 19-105) for the Phase 2 study and 31 days (range, 16-89) for 
the Phase 3 study.   
Several patients were missing baseline and day-80, as indicated by the total number of 
patients contributing to the appropriate analyses summarized below and in Table 2.  Overall, the 
majority of the patients had normal pulmonary function prior to transplantation, defined as a 
percent of the normal predicted value ≥ 80% [FVC 94/114 (82%); FEV1 88/114 (77%); TLC 
105/113 (93%); DLCO 84/114 (74%)].   
Changes in pulmonary function from pretransplantation to day 80 after transplantation 
are summarized in Table 2.  The proportion of BDP- and placebo-treated patients who 
experienced a decrease (of any magnitude) of their pulmonary function from pretransplantation 
to day 80 after transplantation was similar for FVC, FEV1, and TLC, with no statistically 
significant differences.  There was, however, a statistically significant difference in the 
proportion of patients who experienced a decrease of the DLCO (33 of 42 (79%) among placebo-
treated patients, 27 of 49 (55%) in the BDP group, p = 0.02).  Among placebo-treated patients 
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the mean DLCO change was -7.95% (median, -7.17%; range - 40% to +24%), while the mean 
change from baseline to day 80 was +0.57% for BDP-treated patients (median, -0.61%; range -
74% to +115%), the p-value did not exceed the 0.05 threshold (p = 0.08).  These results were 
not qualitatively changed after adjusting for intensity of conditioning (reduced intensity vs. 
myeloablative) (p = 0.009 for proportion experiencing a decrease in DLCO decrease; p = 0.05 for 
the mean DLCO decrease) or after adjusting for age (p = 0.07 for proportion experiencing a 
decrease in DLCO decrease; p = 0.02 for the mean DLCO decrease). 
Among 60 placebo-treated patients, four noninfectious complications occurred within the 
first 200 days after randomization (Figure 1).  These cases were COP/BOOP (at day 39) and 
IPS (at days 69, 148, and 168).  All of these cases occurred after a myeloablative conditioning 
regimen.  Among 60 BDP-treated patients, there were no cases of noninfectious pulmonary 
complications during the first 200 days after randomization (Figure 1).  When considered as a 
time-to-event endpoint, the risk of developing a noninfectious complication within the first 200 
days after randomization was reduced among BDP-treated patients, (p = 0.04).  With only 4 
events, it was not possible to adjust for any factors such as intensity of conditioning or age. 
The causes of pulmonary infections are summarized in Table 3.  Among 60 placebo-
treated patients, 5 cases of pulmonary infection occurred within the first 200 days after 
randomization (Figure 2).  Among 60 BDP-treated patients, 6 cases of pulmonary infection 
occurred during the first 200 days after randomization (Figure 2).  When considered as a time-
to-event endpoint, the risk of developing a pulmonary infection within 200 days following 
randomization was not statistically significantly different between BDP and placebo groups (HR 
= 1.21 (0.37-3.96, p = 0.75)).   
In four patients, peak concentrations of 17-BMP in right atrial blood were achieved at a 
median of 1.5 hours after oral dosing of BDP 2 mg on the morning of study day 50.  The median 
Cmax was 1738 pg/mL (range 632-3701).  Median steady state exposure to 17-BMP was 5347 
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pg.hr/mL (range 3273-5201) as estimated by AUC0-4 hr.  The median half-life of 17-BMP was 6.3 
hours (range 3.1-6.8).  No BDP was detected in right atrial blood. 
Discussion 
The current results suggest that in the context of the original randomized, placebo-controlled 
trials of oral BDP, patients randomized to receive oral BDP were more likely to experience a 
preservation of pulmonary diffusing capacity and fewer episodes of noninfectious pulmonary 
complications compared to placebo-treated patients.  These results are consistent with what is 
known about the pathophysiology of lung function loss and idiopathic lung injury in the aftermath 
of allogeneic HCT and the pharmacology of oral BDP and its potent metabolite, 17-BMP.  
Our finding that DLCO decrease appears to be less pronounced among the BDP-treated 
patients is interesting.  The DLCO measures the patient’s ability to absorb alveolar gases into the 
capillary blood flow, reflecting alveolar membrane thickness, hematocrit level, cardiac output 
and heterogeneity in the distribution of the diffusion capacity to regional ventilation and 
perfusion (in patients with pulmonary disease).26,27  It is well known that systemic inflammation, 
such as that which can occur in the early post-transplant period, can result in pulmonary 
inflammation, which ultimately can cause thickening of the pulmonary interstitium and 
decreased DLCO.  In such a setting, direct delivery of BDP to the pulmonary interstitium via the 
pulmonary artery may serve to reduce inflammation within the lungs, thereby minimizing the 
DLCO reduction commonly observed after allogeneic HCT.   
According to a National Institutes of Health workshop, IPS is loosely defined as 
“evidence of widespread alveolar injury in the absence of active lower respiratory tract infection” 
3. In the modern era of hematopoietic cell transplantation, early HCT-related noninfectious 
pulmonary complications such as IPS generally occur within the first six months after 
transplantation,24 with a reported incidence of 3 to 15%.28-30  There is an accumulating body of 
evidence from murine models of lung injury after allogeneic HCT that strongly suggests that 
  Page 12  
inflammation plays a significant role in the pathogenesis of IPS.  Some of these murine studies 
have established a causal role for TNF-α in the development of IPS, where administration of a 
TNF-α binding protein (rhTNFR:Fc) reduces the progression of lung injury during the four-to-six-
week period after HCT.12,31-33  Other studies have also suggested that lipopolysaccharide (LPS), 
which often gains access to systemic circulation early in the post-transplantation period by 
translocating across gut mucosa damaged by conditioning regimens and acute GVHD,34-36 may 
result in a significant inflammatory cytokine milieu in the lung that results in lung injury.9,35  
Collectively, these data provide strong evidence that overwhelming inflammation within the 
lungs likely plays a significant role in the pathogenesis of early noninfectious pulmonary 
complications after HCT.  Direct delivery of a potent corticosteroid such as oral BDP to the lungs 
via the pulmonary circulation may attenuate the inflammation and prevent the development of 
IPS.  An alternative biologic explanation for the positive effects of oral BDP on these pulmonary 
endpoints is that less gut GVHD reduces gut translocation of bacteria and endotoxin, and thus, 
reduces pulmonary exposure to translocated LPS and inflammatory cytokines.  However, we 
feel that this mechanism is less likely than that of pulmonary delivery of the potent metabolite 
17-BMP because the primary site of 17-BMP activity in patients enrolled in these protocols was 
the upper gut, not the colon, which is where Gram-negative bacteria primarily reside and LPS 
translocation occurs. 
Oral formulations of BDP were developed for treatment of inflammatory bowel disease, 
where they proved to be effective.37-39  However, while inhaled BDP has been used as inhaled 
formulations for the treatment of asthma and chronic inflammatory airway disease for over 35 
years,40 oral BDP does not seem to have been evaluated for the treatment of pulmonary 
diseases, perhaps because of the assumed adverse effects associated with systemic 
corticosteroid therapy.  The formulations of oral BDP used in the randomized trials described 
here included a gastric-release pill for distribution of BDP to the stomach and upper small 
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intestine, and an enteric-coated pill for distribution to the distal small intestine and colon.  
Presence of 17-BMP in the blood from the right heart, as demonstrated by our data, suggests 
that 17-BMP, a product of gastrointestinal mucosal hydrolysis of BDP, was likely absorbed in 
the gastrointestinal tract and entered the right heart via portal venous circulation.  In the HCT 
situation, we speculate that steady-state delivery of 17-BMP to the pulmonary circulation and 
ultimately the interstitial space prior to the onset of clinically detectable disease was responsible 
for reducing pulmonary inflammation, reflected by the preservation of pulmonary diffusing 
capacity and by the absence of noninfectious pulmonary infiltrates within the first 200 days after 
randomization 
Oral BDP also has several advantages over other corticosteroid options from a 
pharmacodynamics perspective.  First, although BDP itself is a relatively weak 
immunosuppressive glucocorticoid, its active metabolite 17-BMP, is a highly potent 
glucocorticoid;17-BMP is 3.6-times more potent than triamcinolone-16,17-acetonide, the active 
ingredient in Azmacort inhalation aerosol (Kos Pharmaceuticals) and 450-times more potent 
than dexamethasone.41  Second, because 17-BMP’s glucocorticoid receptor-α activity is 13-
times more potent than dexamethasone,42 it can be administered at significantly lower doses.  
Third, due to the pulmonary “first pass” effect, higher 17-BMP concentration can be achieved in 
the lung with relatively small doses.  Small doses of 17-BMP can be delivered to the pulmonary 
artery in milligram quantities per day after ingestion of 8 mg oral BDP, which is four- to eight-fold 
higher than can be delivered via inhaled BDP.  Finally, the relative bioavailability of BDP and its 
metabolites is much lower in comparison to more commonly used systemic corticosteroids.  In a 
bioavailability study of oral BDP, no BDP was detectable in the plasma following oral 
administration.  Although the total oral bioavailability of the active metabolite 17-BMP was 21-
41%,43 systemic exposure to 17-BMP is limited by its protein binding and clearance, such that 
oral BDP 2 mg would give systemic exposure equivalent to a dosing schedule of oral 
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prednisone of 2.5 mg or less than 1 mg of intravenous dexamethasone (DOR BioPharma, Inc., 
unpublished data).  These factors, in conjunction with the fact that distribution of 17-BMP into 
the pulmonary interstitial space is likely considerably greater with pulmonary artery delivery than 
the inhaled route, makes oral BDP worthy of further investigation for pulmonary diseases rooted 
in any inflammatory pathophysiology. 
Several limitations should be recognized when interpreting the results of this study.  
First, since the original trials were neither powered nor designed to address pulmonary issues, 
they are not optimal for examining the true potential of oral BDP as a prophylaxis therapy for 
noninfectious pulmonary complications.  Such a study would require the intervention to be 
initiated at the time of transplant and probably with a longer duration of treatment, not to 
mention a substantially larger number of patients.  Second, the size of the current study is 
limiting, not only with respect to statistical power, but also because we were not able to adjust 
for important factors that may influence the risk for developing noninfectious complications.  For 
instance, despite the randomized design, more patients in the oral BDP arm of the phase III 
study received a reduced-intensity conditioning regimen, which has been previously found to be 
associated with a lower incidence of IPS.24  However, even based upon the conservative 
estimates among reduced intensity regimen recipients, it would be expected that IPS should 
have been observed in at least 2.2% of the placebo treated group (if not 8%).24  Finally, while 
the DLCO results are interesting, the DLCO data need to be interpreted with caution.  The clinical 
implication of small percentage changes in DLCO, such as that we have detected, are not readily 
obvious, especially in a transplant setting, where there are many clinical variables that can 
influence the DLCO. 
In summary, the current data suggest that oral BDP treatment was associated with a 
lower incidence of noninfectious pulmonary complications and that delivery of a potent 
glucocorticoid (17-BMP) to the pulmonary artery may be useful in modulating pulmonary 
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inflammation after allogeneic HCT.  We emphasize that we consider these data to be 
hypothesis generating due to the limitations cited above. As such, these findings are not 
sufficient to justify the use of oral BDP to prevent noninfectious pulmonary complications, but 
should guide future studies designed to definitively address the potential of BDP to lower the 
risk of noninfectious pulmonary complications and assess the potential adverse events 
associated with prolonged oral BDP use. 
 
Acknowledgements: The randomized placebo-controlled trials on which these data are based 
were supported by Orphan Products Development Grants from the U.S. Food and Drug 
Administration (FD-R 000827 and FD-R 02599) and by Enteron Pharmaceuticals, Inc., a wholly 
owned subsidiary of DOR BioPharma, Ewing, NJ.  This research was supported by grants from 
the National Institutes of Health, National Cancer Institute (CA18029 and CA15704). 
 
  Page 16  
Reference List 
 
 
 1.   Cordonnier C, Bernaudin J-F, Bierling P, Huet Y, Vernant J-P.  Pulmonary complications 
occurring after allogeneic bone marrow transplantation.  A study of 130 consecutive 
transplanted patients. Cancer 1986; 58: 1047-1054. 
 2.   Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC.  Pulmonary complications in 
lymphoma patients treated with high-dose therapy autologous bone marrow 
transplantation. Am Rev Respir Dis 1992; 146: 485-491. 
 3.   Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH.   NHLBI workshop 
summary: idiopathic pneumonia syndrome after bone marrow transplantation [Review]. 
Am Rev Respir Dis 1993; 147: 1601-1606. 
 4.   Shankar G, Cohen DA.   Idiopathic pneumonia syndrome after bone marrow 
transplantation: the role of pre-transplant radiation conditioning and local cytokine 
dysregulation in promoting lung inflammation and fibrosis (Review). Int J Exp Pathol 2001; 
82: 101-113. 
 5.   Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG.   Diffuse alveolar 
hemorrhage in hematopoietic stem cell transplant recipients (Review). Am J Respir Crit 
Care Med 2002; 166: 641-645. 
 6.   Afessa B, Tefferi A, Litzow MR, Peters SG.   Outcome of diffuse alveolar hemorrhage in 
hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166: 1364-
1368. 
 7.   Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R, et al.   Lethal 
pulmonary complications significantly correlate with individually assessed mean lung dose 
  Page 17  
in patients with hematologic malignancies treated with total body irradiation. Int J Radiat 
Oncol Biol Phys 2002; 52: 483-488. 
 8.   Clark JG, Madtes DK, Hackman RC, Chen W, Cheever MA, Martin PJ.   Lung injury 
induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell 
inflammation and activation of alveolar macrophages. J Immunol 1998; 161: 1913-1920. 
 9.   Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte JJ, Crawford JM, et al.   An 
experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: 
I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239. 
 10.   Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, Wangensteen OD, Bitterman PB, Ingbar 
DH, et al.   The critical early proinflammatory events associated with idiopathic pneumonia 
syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and 
potentiated by cyclophosphamide. J Clin Invest 1997; 100: 1015-1027. 
 11.   Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW.   Idiopathic 
pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide 
amplification in the bronchoalveolar compartment. Crit Care Med 1999; 27: 1800-1806. 
 12.   Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al.   Tumor necrosis 
factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow 
transplantation. Transplantation 2000; 70: 272-279. 
 13.   Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, et al.   Fatal 
human metapneumovirus infection in stem cell transplant recipients. Ann Intern Med 2006; 
144: 344-349. 
  Page 18  
 14.   Broliden K.   Parvovirus B19 infection in pediatric solid-organ and bone marrow 
transplantation (Review). Pediatr Transplant 2001; 5: 320-330. 
 15.   McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, et al.   Oral 
beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a 
randomized, controlled trial. Gastroenterology 1998; 115: 28-35. 
 16.   Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, et al.   A 
randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-
sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557-
4563. 
 17.   McDonald GB.   Oral beclomethasone dipropionate: a topically active corticosteroid for the 
treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic 
cell transplantation (Review). Expert Opin Investig Drugs 2007; 16: 1709-1724. 
 18.   Standardization of spirometry, 1994 update: American Thoracic Society. Am J Respir Crit 
Care Med 1995; 152: 1107-1136. 
 19.   Lung function testing: selection of reference values and interpretative strategies. American 
Thoracic Society. Am Rev Respir Dis 1991; 144: 1202-1218. 
 20.   American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer 
factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care 
Med 1995; 152: 2185-2198. 
 21.   Crapo RO, Morris AH, Gardner RM.   Reference spirometric values using techniques and 
equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664. 
  Page 19  
 22.   Crapo RO, Morris AH.   Standardized single breath normal values for carbon monoxide 
diffusing capacity. Am Rev Respir Dis 1981; 123: 185-189. 
 23.   Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC.    
Association between acute and chronic graft-versus-host disease and bronchiolitis 
obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. 
Blood 2003; 102: 3822-3828. 
 24.   Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, et al.   Risks 
and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional 
conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 
102: 2777-2785. 
 25.   Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA.   Bronchiolitis obliterans 
organizing pneumonia. N Engl J Med 1985; 312: 152-158. 
 26.   Crapo RO, Forster RE.   Carbon monoxide diffusing capacity (Review). Clin Chest Med 
1989; 10: 187-198. 
 27.   Yamaguchi K, Mori M, Kawai A, Takasugi T, Oyamada Y, Koda E.   Inhomogeneities of 
ventilation and the diffusing capacity to perfusion in various chronic lung diseases. Am J 
Respir Crit Care Med 1997; 156: 86-93. 
 28.   Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HEM, Kolb H-J, et al.   Interstitial 
pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104: 168-175. 
 29.   Crawford SW, Longton G, Storb R.   Acute graft-versus-host disease and the risks for 
idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone 
Marrow Transplant 1993; 12: 225-231. 
  Page 20  
 30.   Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW.   Idiopathic pneumonia 
syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 
1997; 63: 1079-1086. 
 31.   Piguet P-F, Grau GE, Allet B, Vassalli P.   Tumor necrosis factor/cachectin is an effector of 
skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166: 
1280-1289. 
 32.   Hildebrandt GC, Olkiewicz KM, Corrion LA, Chang Y, Clouthier SG, Liu C, et al.   Donor-
derived TNF-alpha regulates pulmonary chemokine expression and the development of 
idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 
104: 586-593. 
 33.   Hildebrandt GC, Olkiewicz KM, Corrion L, Clouthier SG, Pierce EM, Liu C, et al.   The role 
for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic 
pneumonia syndrome. Biol Blood Marrow Transplant 2008; 14: 385-396. 
 34.   Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL.   Total body irradiation 
and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory 
cytokines. Blood 1997; 90: 3204-3213. 
 35.   Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J, Jr., et al.   Tumor 
necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts 
the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 
1882-1891. 
 36.   Nestel FP, Price KS, Seemayer TA, Lapp WS.   Macrophage priming and 
lipopolysaccharide-triggered release of tumor necrosis factor   during graft-versus-host 
disease. J Exp Med 1992; 175: 405-413. 
  Page 21  
 37.   Levine DS.   Immune modulating therapies for idiopathic inflammatory bowel diseases. 
Adv Pharmacol 1994; 25: 171-234. 
 38.   Raj RM, Hendrix TR, Moskaluk C, Levine DS, Pasricha PJ.   Treatment of idiopathic 
lymphocytic enterocolitis with oral beclamethasone dipropionate. Am J Gastroenterol 
1997; 92: 147-149. 
 39.   Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, et al.   Oral 
beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind 
placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-1116. 
 40.   Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS.   Beclomethasone 
dipropionate inhaler: a review of its pharmacology, therapeutic value and adverse effects. 
I: Asthma. Drugs 1975; 10: 166-210. 
 41.   Harris DM.   Properties and therapeutic uses of some corticosteroids with enhanced 
topical potency. J Steroid Biochem 1975; 6: 711-716. 
 42.   Wurthwein G, Rohdewald P.   Activation of beclomethasone dipropionate by hydrolysis to 
beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990; 11: 381-394. 
 43.   Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N.   Beclomethasone 
dipropionate: absolute bioavailability, pharmacokinetics and metabolism following 
intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 
51: 400-409. 
 
 
 
  Page 22  
  Page 23  
Table 1.  Characteristics of BDP and placebo treated patients 
   
Characteristics Placebo (N=60) BDP (N=60) 
   
Median age (range) 47 (12-66) 40 (7-67) 
Recipient: donor sex 
M:M 
M:F 
F:F 
F:M 
 
17 
11 
12 
20 
 
24 
12 
9 
15 
Disease 
CML 
AML 
MDS 
ALL 
NHL 
Other 
 
13 
16 
17 
8 
2 
4 
 
15 
19 
3 
8 
8 
7 
Donor type 
Unrelated 
Related matched 
Related mismatched 
 
24 
31 
3 
 
20 
32 
7 
Conditioning regimen 
TBI-based myeloablative 
Non-TBI-based myeloablative 
Reduced intensity 
 
28 
28 
4 
 
31 
18 
11 
Randomized study 
Phase II 
Phase III 
 
29 
31 
 
31 
29 
Pulmonary function 
pretransplant * 
FVC 
FEV1  
TLC  
DLCO  
 
 
95.1 
89.9 
98.6 
90.9 
 
 
93.7 
90.4 
95.7 
83.6 
Pulmonary function at day 80 * 
FVC  
FEV1  
TLC  
DLCO  
 
93.0 
89.2 
96.7 
81.2 
 
93.8 
90.3 
96.9 
86.0 
M=male; F=female; CML=chronic myeloid leukemia; AML=acute myeloid leukemia; 
MDS=myelodysplastic syndrome; ALL=acute lymphocytic leukemia; NHL=non-Hodgkins 
lymphoma; TBI=total body irradiation, FVC=forced vital capacity, FEV1=one second forced 
expiratory volume, TLC=total lung capacity, DLCO=diffusion capacity of carbon monoxide  
*Numbers represent the mean of the percent of predicted normal values;  
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Table 2.  Change in pulmonary function from pretransplant to day 80 
    
PFT parameter Placebo BDP p-value 
    
FEV1    
N (%)* 21/44 (48%) 25/50 (50%) 0.83 
Mean change (range) -1.38 (-25, +19) -0.05 (-22, +34) 0.48 
FVC    
N (%)* 24/44 (55%) 25/50 (50%) 0.66 
Mean change (range) -1.85 (-20, +16) +0.34 (-30, +35) 0.26 
TLC    
N (%)* 25/42 (60%) 29/50 (58%) 0.88 
Mean change (range) -1.67 (-20, +23) +1.41 (-25, +57) 0.23 
DLCO    
N (%)* 33/42 (79%) 27/49 (55%) 0.02 
Mean change (range) -7.95 (-40, +23) +0.57 (-74, +115) 0.08 
        
  
FVC=forced vital capacity, FEV1=one second forced expiratory volume, TLC=total lung capacity, 
DLCO=diffusion capacity of carbon monoxide 
*N represents proportion of patients who experienced a decrease in that parameter 
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Table 3.  Causes of pulmonary infection according to treatment group 
    
Placebo Oral BDP 
    
Cause of infection Day post-
randomization 
Cause of infection               Day post-randomization 
Fungal, nonspecific 41 Legionella spp. 27 
Aspergillus fumigatus 59 Polymicrobial bacteria 31 
Unknown cause 125 Pseudomonas 
aeruginosa 
48 
Aspergillus spp, 142 Candida glabrata 83 
Unknown cause 143 Unknown cause 85 
  Unknown cause 104 
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Figure 1.  
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Figure Legends 
Figure 1.  Cumulative incidence of non-infectious pulmonary complications after treatment 
randomization.  Prior to day 200 after treatment randomization, no cases of non-infectious 
pulmonary complications occurred among the BDP-treated patients. 
Figure 2.  Cumulative incidence of pulmonary infections after treatment randomization. There 
was not a statistically significant difference in the risk of pulmonary infections between the two 
treatment groups. 
 
 
